{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:10:41Z","timestamp":1783959041363,"version":"3.55.0"},"reference-count":109,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>Polycystic ovarian syndrome (PCOS) is a common problem among young women. It is characterized mainly by hyperandrogenism features, such as hirsutism, menstrual problems, and anovulation. Diagnosis is based on the existence of 2 items out of, oligo-ovulation, hyperandrogenism features, and ultrasounds findings. Cardiovascular complications such as hypertension are a prevalent serious condition in these patients which is mainly predisposed by the high levels of androgens, and insulin resistance. High blood pressure should be controlled well to prevent the progression of other serious conditions. Various antihypertensive drugs could be prescribed. However, in selecting an antihypertensive medication, other therapeutic properties of the drug should also be considered. Up to now, many clinicians do not differ between PCOS patients with hypertension and other hypertensive patients. However, being aware of the potential effects of each hypertension drug could help to choose better options for the patient. Here is a brief review of how each antihypertensive drug could affect PCOS women and if they cause any improvement in the disorder progression.<\/jats:p>","DOI":"10.1097\/crd.0000000000000635","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T09:03:37Z","timestamp":1706864617000},"page":"431-436","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Management of Hypertension in Patients With Polycystic Ovarian Syndrome: A Mini-Review"],"prefix":"10.1097","volume":"33","author":[{"given":"Amin","family":"Liaghatdar","sequence":"first","affiliation":[{"name":"From the Heart Failure Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadegh","family":"Mazaheri-Tehrani","sequence":"additional","affiliation":[{"name":"From the Heart Failure Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Fakhrolmobasheri","sequence":"additional","affiliation":[{"name":"From the Heart Failure Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"R1-20260713","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1210\/js.2019-00078","article-title":"Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls.","volume":"3","author":"Witchel","year":"2019","journal-title":"J Endocr Soc"},{"key":"R2-20260713","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"key":"R3-20260713","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1741-7015-8-41","article-title":"Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan.","volume":"8","author":"Teede","year":"2010","journal-title":"BMC Med"},{"key":"R4-20260713","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1161\/01.ATV.15.7.821","article-title":"Coronary heart disease risk factors in women with polycystic ovary syndrome.","volume":"15","author":"Talbott","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R5-20260713","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/humupd\/dmaa029","article-title":"Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis.","volume":"26","author":"Wekker","year":"2020","journal-title":"Hum Reprod Update"},{"key":"R6-20260713","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1210\/clinem\/dgab134","article-title":"Incidence and predictors of hypertension in a cohort of Australian women with and without polycystic ovary syndrome.","volume":"106","author":"Joham","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-20260713","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12958-020-00576-1","article-title":"Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression.","volume":"18","author":"Amiri","year":"2020","journal-title":"Reprod Biol Endocrinol"},{"key":"R8-20260713","first-page":"55","article-title":"Hypertension in polycystic ovary syndrome: novel insights.","volume":"16","author":"Macut","year":"2020","journal-title":"Curr Hypertens Rev"},{"key":"R9-20260713","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1210\/jc.2006-0399","article-title":"Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome.","volume":"91","author":"Cascella","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R10-20260713","doi-asserted-by":"crossref","first-page":"574651","DOI":"10.3389\/fmed.2020.574651","article-title":"Hypertension risk in young women with polycystic ovary syndrome: a nationwide population-based cohort study.","volume":"7","author":"Wu","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"R11-20260713","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2217\/17455057.4.6.583","article-title":"Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome.","volume":"4","author":"Christakou","year":"2008","journal-title":"Womens Health (Lond)"},{"key":"R12-20260713","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.3390\/ijms21249554","article-title":"Pharmacological approaches to controlling cardiometabolic risk in women with PCOS.","volume":"21","author":"Cignarella","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R13-20260713","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.fertnstert.2018.05.004","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.","volume":"110","author":"Teede","year":"2018","journal-title":"Fertil Steril"},{"key":"R14-20260713","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1210\/jc.2018-02496","article-title":"Family-based quantitative trait meta-analysis implicates rare noncoding variants in DENND1A in polycystic ovary syndrome.","volume":"104","author":"Dapas","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-20260713","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1210\/jc.2018-02178","article-title":"Functional genetic variation in the anti-m\u00fcllerian hormone pathway in women with polycystic ovary syndrome.","volume":"104","author":"Gorsic","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-20260713","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1210\/jc.2007-0267","article-title":"Anti-M\u00fcllerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome.","volume":"92","author":"Crisosto","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-20260713","doi-asserted-by":"crossref","first-page":"14956","DOI":"10.1073\/pnas.95.25.14956","article-title":"Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.","volume":"95","author":"Legro","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R18-20260713","first-page":"71","article-title":"Manipulation of human ovarian function: physiological concepts and clinical consequences*.","volume":"18","author":"Fauser","year":"1997","journal-title":"Endocr Rev"},{"key":"R19-20260713","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1210\/jcem-66-1-165","article-title":"Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization*.","volume":"66","author":"Waldstreicher","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-20260713","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/cen.14421","article-title":"Obesity and polycystic ovary syndrome.","volume":"95","author":"Barber","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R21-20260713","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0889-8529(18)30405-5","article-title":"Hyperinsulinemia and ovarian hyperandrogenism Cause and effect.","volume":"17","author":"Barbieri","year":"1988","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R22-20260713","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/er.2011-1034","article-title":"Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.","volume":"33","author":"Diamanti-Kandarakis","year":"2012","journal-title":"Endocr Rev"},{"key":"R23-20260713","doi-asserted-by":"crossref","first-page":"101236","DOI":"10.1016\/j.molmet.2021.101236","article-title":"Insulin\u2019s actions on vascular tissues: physiological effects and pathophysiological contributions to vascular complications of diabetes.","volume":"52","author":"Fu","year":"2021","journal-title":"Mol Metab"},{"key":"R24-20260713","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0002-9149(99)00354-9","article-title":"Vascular reactivity.","volume":"84","author":"Baron","year":"1999","journal-title":"Am J Cardiol"},{"key":"R25-20260713","doi-asserted-by":"crossref","first-page":"H2009","DOI":"10.1152\/ajpheart.00522.2007","article-title":"Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance.","volume":"293","author":"Cooper","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R26-20260713","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1159\/000351572","article-title":"Increased total renin levels but not angiotensin-converting enzyme activity in obese patients with polycystic ovary syndrome.","volume":"22","author":"Alphan","year":"2013","journal-title":"Med Princ Pract"},{"key":"R27-20260713","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.steroids.2012.02.010","article-title":"Polycystic ovary syndrome: implications of measurement of plasma aldosterone, renin activity and progesterone.","volume":"77","author":"Armanini","year":"2012","journal-title":"Steroids"},{"key":"R28-20260713","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.3390\/ijms23084110","article-title":"Controversies in the pathogenesis, diagnosis and treatment of PCOS: focus on insulin resistance, inflammation, and hyperandrogenism.","volume":"23","author":"Armanini","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R29-20260713","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1210\/jc.2004-0934","article-title":"Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome.","volume":"89","author":"Yildiz","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R30-20260713","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1210\/jc.2003-030240","article-title":"Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.","volume":"88","author":"Tsilchorozidou","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R31-20260713","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1161\/01.HYP.19.5.456","article-title":"Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats.","volume":"19","author":"Chen","year":"1992","journal-title":"Hypertension"},{"key":"R32-20260713","doi-asserted-by":"crossref","first-page":"F452","DOI":"10.1152\/ajprenal.00188.2003","article-title":"Androgens augment proximal tubule transport.","volume":"287","author":"Quan","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"R33-20260713","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/01.HYP.0000184362.61744.c1","article-title":"Androgen receptor-mediated regulation of the alpha-subunit of the epithelial sodium channel in human kidney.","volume":"46","author":"Quinkler","year":"2005","journal-title":"Hypertension"},{"key":"R34-20260713","doi-asserted-by":"crossref","first-page":"R1055","DOI":"10.1152\/ajpregu.00459.2002","article-title":"Androgen-mediated induction of the kidney arachidonate hydroxylases is associated with the development of hypertension.","volume":"284","author":"Nakagawa","year":"2003","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R35-20260713","first-page":"R607","article-title":"20-HETE and the kidney: resolution of old problems and new beginnings.","volume":"277","author":"McGiff","year":"1999","journal-title":"Am J Physiol"},{"key":"R36-20260713","doi-asserted-by":"crossref","first-page":"H1089","DOI":"10.1152\/ajpheart.00627.2003","article-title":"Transfection of CYP4A1 cDNA decreases diameter and increases responsiveness of gracilis muscle arterioles to constrictor stimuli.","volume":"287","author":"Zhang","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R37-20260713","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3109\/09513590.2012.743015","article-title":"Effects of androgen on vascular and inflammatory biomarkers in a female hypertensive population.","volume":"29","author":"Huang","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"R38-20260713","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jtcme.2018.02.001","article-title":"Mechanism & inhibition kinetics of bioassay-guided fractions of Indian medicinal plants and foods as ACE inhibitors.","volume":"9","author":"Khan","year":"2019","journal-title":"J Tradit Complement Med"},{"key":"R39-20260713","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jcph.1872","article-title":"The impact of telmisartan on cardiometabolic risk factors in hypertensive male siblings of women with polycystic ovary syndrome.","volume":"61","author":"Krysiak","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"S9","key":"R40-20260713","doi-asserted-by":"crossref","first-page":"205S","DOI":"10.1016\/S0895-7061(99)00103-X","article-title":"The renin-angiotensin-aldosterone system: a specific target for hypertension management.","volume":"12","author":"Weir","year":"1999","journal-title":"Am J Hypertens"},{"key":"R41-20260713","first-page":"9","article-title":"The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition.","volume":"13","author":"Atlas","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"R42-20260713","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1524-6175.2005.05141.x","article-title":"Angiotensin receptor blockers: new considerations in their mechanism of action.","volume":"8","author":"Sica","year":"2006","journal-title":"J Clin Hypertens"},{"key":"R43-20260713","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.2021.35.S1.04291","article-title":"Effect of Angiotensin-converting Enzyme Inhibition on Systemic and Renal RAS Components in a Hyperandrogenemic Rat Model of PCOS.","volume":"35","author":"Everman","year":"2021","journal-title":"FASEB J"},{"key":"R44-20260713","doi-asserted-by":"crossref","first-page":"E53","DOI":"10.1111\/rda.12384","article-title":"Inhibition of Angiotensin-Converting Enzyme Increases Oestradiol Production in Ewes Submitted to Oestrous Synchronization Protocol.","volume":"49","author":"Costa","year":"2014","journal-title":"Reprod Domest Anim"},{"key":"R45-20260713","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/rda.13180","article-title":"ACE inhibition in goats under fixed-time artificial insemination protocol increases the pregnancy rate and twin births.","volume":"53","author":"Fernandes Neto","year":"2018","journal-title":"Reprod Domest Anim"},{"key":"R46-20260713","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.rbmo.2020.09.011","article-title":"Effects of lisinopril treatment on the pathophysiology of PCOS and plasminogen activator inhibitor-1 concentrations in rats.","volume":"42","author":"Coskun","year":"2021","journal-title":"Reprod Biomed Online"},{"key":"R47-20260713","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0015-0282(01)03210-1","article-title":"Effect of hypertension therapy with the angiotensin-converting enzyme inhibitor lisinopril on hyperandrogenism in women with polycystic ovary syndrome.","volume":"77","author":"Hacihanefioglu","year":"2002","journal-title":"Fertil Steril"},{"key":"R48-20260713","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"R49-20260713","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3325\/cmj.2007.6.864","article-title":"Decreased androgen levels and improved menstrual pattern after angiotensin II receptor antagonist telmisartan treatment in four hypertensive patients with polycystic ovary syndrome: case series.","volume":"48","author":"Jensterle","year":"2007","journal-title":"Croat Med J"},{"key":"R50-20260713","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"R52-20260713","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/00002512-199303040-00007","article-title":"Diltiazem. A review of its pharmacology and therapeutic use in older patients.","volume":"3","author":"Markham","year":"1993","journal-title":"Drugs Aging"},{"key":"R53-20260713","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/1074248414555403","article-title":"Calcium channel blockers and hypertension.","volume":"20","author":"Tocci","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R54-20260713","first-page":"089","article-title":"Can amlodipine improve the pre-ovulatory follicle blood flow in women with polycystic ovarian syndrome?","volume":"20","author":"Faham","year":"2019","journal-title":"J Reprod Infertil"},{"key":"R55-20260713","first-page":"3346","article-title":"Nitrendipine treatment in women with polycystic ovarian syndrome: evidence for a lack of effects of calcium channel blockers on insulin, androgens, and sex hormone-binding globulin.","volume":"80","author":"Pasquali","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"R56-20260713","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1477-7827-11-7","article-title":"Nimodipine, a calcium channel blocker, delays the spontaneous LH surge in women with regular menstrual cycles: a prospective pilot study.","volume":"11","author":"Nayot","year":"2013","journal-title":"Reprod Biol Endocrinol"},{"key":"R57-20260713","doi-asserted-by":"crossref","first-page":"A3","DOI":"10.1016\/0002-9149(93)90238-8","article-title":"Aldosterone and antialdosterone therapy in congestive heart failure.","volume":"71","author":"Weber","year":"1993","journal-title":"Am J Cardiol"},{"key":"R58-20260713","first-page":"454","article-title":"Triamterene and the kidney.","volume":"51","author":"Sica","year":"1989","journal-title":"Nephron"},{"key":"R59-20260713","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone.","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"key":"R60-20260713","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/jch.13385","article-title":"Vascular compliance in women with polycystic ovary syndrome treated with spironolactone.","volume":"20","author":"Muneyyirci-Delale","year":"2018","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R61-20260713","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro.","volume":"240","author":"de Gasparo","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"R62-20260713","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1530\/EJE-10-0709","article-title":"Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome.","volume":"164","author":"Bajuk Studen","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"R63-20260713","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s40200-022-01097-x","article-title":"Mineralocorticoid receptor blockade attenuates hyperandrogenic metabolic dysregulation in letrozole-induced PCOS rat model.","volume":"21","author":"Uhunmwangho","year":"2022","journal-title":"J Diabetes Metab Disord"},{"key":"R64-20260713","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.numecd.2013.04.016","article-title":"In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.","volume":"24","author":"Mazza","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R65-20260713","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1210\/jc.2013-1040","article-title":"Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.","volume":"98","author":"Ganie","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R66-20260713","doi-asserted-by":"crossref","first-page":"115381","DOI":"10.1016\/j.taap.2020.115381","article-title":"Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS.","volume":"411","author":"Olaniyi","year":"2021","journal-title":"Toxicol Appl Pharmacol"},{"key":"R67-20260713","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2003-39781","article-title":"Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes.","volume":"111","author":"Boden","year":"2003","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"R68-20260713","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3109\/09513590.2013.769515","article-title":"Serum free fatty acid levels in PCOS patients treated with glucophage, magnesium oxide and spironolactone.","volume":"29","author":"Muneyyirci-Delale","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"R69-20260713","article-title":"Beta-blockers for hypertension.","volume":"2017","author":"Wiysonge","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R70-20260713","first-page":"22","article-title":"Three generations of \u03b2-blockers: history, class differences and clinical applicability.","volume":"14","author":"Tavares","year":"2018","journal-title":"Curr Hypertens Rev"},{"key":"R71-20260713","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.lfs.2005.04.008","article-title":"Combined effects of oleoyl-estrone and a \u03b23-adrenergic agonist (CL316,243) on lipid stores of diet-induced overweight male Wistar rats.","volume":"77","author":"Ferrer-Lorente","year":"2005","journal-title":"Life Sci"},{"key":"R72-20260713","first-page":"417","article-title":"Third generation beta blockers in the treatment of hypertension.","volume":"38","author":"Widimsk\u00fd","year":"1992","journal-title":"Vnitr Lek"},{"key":"R73-20260713","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/01.CIR.0000066912.58385.DE","article-title":"Third-generation \u03b2-blockers stimulate nitric oxide release from endothelial cells through ATP efflux.","volume":"107","author":"Kalinowski","year":"2003","journal-title":"Circulation"},{"key":"R74-20260713","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1172\/JCI21737","article-title":"Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin.","volume":"114","author":"Rahmouni","year":"2004","journal-title":"J Clin Invest"},{"key":"R75-20260713","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/01.HYP.0000091371.53502.D3","article-title":"Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation.","volume":"42","author":"Masuo","year":"2003","journal-title":"Hypertension"},{"key":"R76-20260713","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0015-0282(01)01805-2","article-title":"Increase in nerve fibers and loss of mast cells in polycystic and postmenopausal ovaries.","volume":"75","author":"Heider","year":"2001","journal-title":"Fertil Steril"},{"key":"R77-20260713","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/cen.12003","article-title":"The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target?","volume":"77","author":"Lansdown","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R78-20260713","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1055\/s-0031-1301304","article-title":"In vivo \u03d0-adrenergic blockade by propranolol prevents isoproterenol-induced polycystic ovary in adult rats.","volume":"44","author":"Luna","year":"2012","journal-title":"Horm Metab Res"},{"key":"R79-20260713","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12958-019-0539-y","article-title":"In rats with estradiol valerate-induced polycystic ovary syndrome, the acute blockade of ovarian \u03b2-adrenoreceptors improve ovulation.","volume":"17","author":"Venegas","year":"2019","journal-title":"Reprod Biol Endocrinol"},{"key":"R80-20260713","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"R81-20260713","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/13880209.2015.1014922","article-title":"Dual targeting of TNF-\u03b1 and free radical toxic stress as a promising strategy to manage experimental polycystic ovary.","volume":"54","author":"Rezvanfar","year":"2016","journal-title":"Pharm Biol"},{"key":"R82-20260713","doi-asserted-by":"crossref","first-page":"4579831","DOI":"10.1155\/2022\/4579831","article-title":"Role of oxidative stress in obese and nonobese PCOS patients.","volume":"2022","author":"U\u00e7kan","year":"2022","journal-title":"Int J Clin Pract"},{"key":"R83-20260713","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2337\/dc14-1596","article-title":"Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.","volume":"38","author":"Majewski","year":"2015","journal-title":"Diabetes Care"},{"key":"R84-20260713","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40265-014-0225-5","article-title":"Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.","volume":"74","author":"Plosker","year":"2014","journal-title":"Drugs"},{"key":"R85-20260713","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.3390\/ijms22052576","article-title":"Impact of SGLT-2 inhibition on cardiometabolic abnormalities in a rat model of polycystic ovary syndrome [Published Last Modified Date| Accessed Dated Accessed|].","volume":"22","author":"Pruett","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R86-20260713","doi-asserted-by":"crossref","first-page":"e3682","DOI":"10.1002\/dmrr.3682","article-title":"Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome.","volume":"39","author":"Lempesis","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"key":"R87-20260713","doi-asserted-by":"crossref","first-page":"932","DOI":"10.4239\/wjd.v12.i7.932","article-title":"Exploring new treatment options for polycystic ovary syndrome: review of a novel antidiabetic agent SGLT2 inhibitor.","volume":"12","author":"Marinkovic-Radosevic","year":"2021","journal-title":"World J Diabetes"},{"key":"R88-20260713","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tem.2014.12.003","article-title":"Metabolic risk in PCOS: phenotype and adiposity impact.","volume":"26","author":"Moran","year":"2015","journal-title":"Trends Endocrinol Metab"},{"key":"R89-20260713","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13293-022-00455-x","article-title":"Mitochondrial function and oxidative stress in white adipose tissue in a rat model of PCOS: effect of SGLT2 inhibition.","volume":"13","author":"Pruett","year":"2022","journal-title":"Biol Sex Differ"},{"key":"R90-20260713","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/cen.13968","article-title":"Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study.","volume":"90","author":"Javed","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R91-20260713","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/dom.14583","article-title":"Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: a randomized, open-label, noninferiority trial.","volume":"24","author":"Cai","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"R92-20260713","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00592-022-01981-1","article-title":"Effect of sodium\u2013glucose cotransporter 2 inhibitors on insulin resistance; a systematic review and meta-analysis.","volume":"60","author":"Fakhrolmobasheri","year":"2023","journal-title":"Acta Diabetol"},{"key":"R93-20260713","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"R94-20260713","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2337\/dc18-0680","article-title":"Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial.","volume":"41","author":"Jabbour","year":"2018","journal-title":"Diabetes Care"},{"key":"R95-20260713","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s40265-014-0324-3","article-title":"Dapagliflozin: a review of its use in patients with type 2 diabetes.","volume":"74","author":"Plosker","year":"2014","journal-title":"Drugs"},{"key":"R96-20260713","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R97-20260713","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 international society of hypertension global hypertension practice guidelines.","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"R98-20260713","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1161\/HYPERTENSIONAHA.106.083972","article-title":"Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome.","volume":"49","author":"Chen","year":"2007","journal-title":"Hypertension"},{"key":"R99-20260713","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jsmc.2007.11.001","article-title":"Polycystic ovary syndrome and obstructive sleep apnea.","volume":"3","author":"Tasali","year":"2008","journal-title":"Sleep Med Clin"},{"key":"R100-20260713","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1080\/09513590.2021.1942452","article-title":"The prevalence of anxiety and depression of different severity in women with polycystic ovary syndrome: a meta-analysis.","volume":"37","author":"Wang","year":"2021","journal-title":"Gynecol Endocrinol"},{"key":"R101-20260713","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.fertnstert.2006.03.037","article-title":"The pregnancy in polycystic ovary syndrome study: baseline characteristics of the randomized cohort including racial effects.","volume":"86","author":"Legro","year":"2006","journal-title":"Fertil Steril"},{"key":"R102-20260713","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/bmb\/ldy035","article-title":"The management of hypertension in women planning for pregnancy.","volume":"128","author":"Lu","year":"2018","journal-title":"Br Med Bull"},{"key":"R103-20260713","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11906-018-0859-x","article-title":"ACE inhibitor-induced angioedema: a review.","volume":"20","author":"Kostis","year":"2018","journal-title":"Curr Hypertens Rep"},{"key":"R104-20260713","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/hrt.2003.019505","article-title":"Atherosclerotic renal artery stenosis, ACE inhibitors, and avoiding cardiovascular death.","volume":"91","author":"Main","year":"2005","journal-title":"Heart"},{"key":"R105-20260713","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1056\/NEJM200003093421006","article-title":"The evaluation and management of bradycardia.","volume":"342","author":"Mangrum","year":"2000","journal-title":"N Engl J Med"},{"key":"R106-20260713","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","article-title":"Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease.","volume":"7","author":"Beldhuis","year":"2019","journal-title":"JACC Heart Fail"},{"key":"R107-20260713","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2466-12-48","article-title":"Beta-blocker use and COPD mortality: a systematic review and meta-analysis.","volume":"12","author":"Etminan","year":"2012","journal-title":"BMC Pulm Med"},{"key":"R108-20260713","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1185\/03007990903533681","article-title":"Effects of beta-blockers on glucose and lipid metabolism.","volume":"26","author":"Fonseca","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"R109-20260713","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"R110-20260713","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:00:55Z","timestamp":1783958455000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":109,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000635","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]}}}